Results 41 to 50 of about 243 (91)

Alzheimer's disease drug development pipeline: 2019

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 5, Issue 1, Page 272-293, 2019., 2019
Abstract Introduction Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices.
Jeffrey Cummings, Garam Lee, Aaron Ritter, Marwan Sabbagh, Kate Zhong   +4 more
wiley   +1 more source

Alzheimer's disease drug development pipeline: 2018

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 4, Issue 1, Page 195-214, 2018., 2018
Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov. Methods Clinicaltrials.gov was assessed as of January
Jeffrey Cummings, Garam Lee, Aaron Ritter, Kate Zhong   +3 more
wiley   +1 more source

The Alzheimer’s Disease THErapy with NEuroaid II (ATHENE) Study: A Double-Blind Randomized Delayed-Start Trial to Assess the Safety and Efficacy of MLC901 (NeuroAiD™II) as an add-on Treatment to Cholinesterase Inhibitors or Memantine in Patients With Mild to Moderate Alzheimer's Disease

, 2021
BackgroundPreclinical and clinical studies indicate a role for MLC901 (NeuroAiDTMII) in Alzheimer’s Disease (AD). We investigated its safety and efficacy as add-on therapy to standard treatment and evaluated a disease modifying effect in mild to ...
C. Chen, Qingshuang Liu, R. B. Moorakonda, N. Kandiah, B. Tan, S. Villaraza, J. Cano, N. Venketasubramanian   +7 more
semanticscholar   +1 more source

The Effects of Chunghyul‐Dan, an Agent of Korean Medicine, on a Mouse Model of Traumatic Brain Injury

Evidence-Based Complementary and Alternative Medicine, Volume 2017, Issue 1, 2017., 2017
Chunghyul‐Dan (CHD) is the first choice agent for the prevention and treatment of stroke at the Kyung Hee Medical Hospital. To date, CHD has been reported to have beneficial effects on brain disease in animals and humans, along with antioxidative and anti‐inflammatory effects.
Won-Woo Choi, Kyungjin Lee, Beom-Joon Lee, Seong-Uk Park, Jung-Mi Park, Chang-Nam Ko, Youngmin Bu, Krishnadas Nandakumar   +7 more
wiley   +1 more source

Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double‐Blind, Placebo‐Controlled Clinical Trial

Stroke Research and Treatment, Volume 2011, Issue 1, 2011., 2011
Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods. This study was a double‐blind, placebo‐controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50
A. A. Harandi, R. Abolfazli, A. Hatemian, K. Ghragozlee, M. Ghaffar-Pour, M. Karimi, S. Shahbegi, H. Pakdaman, M. Tabasi, A. L. Tabatabae, A. Nourian, Daniel Bereczki   +11 more
wiley   +1 more source

MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats

Neuroscience, 2014
Traumatic brain injury (TBI) is a frequent and clinically highly heterogeneous neurological disorder with large socioeconomic consequences. NeuroAid (MLC601 and MLC901), a Traditional Medicine used in China for patients after stroke has been previously reported to induce neuroprotection and neuroplasticity.
Quintard, H., Lorivel, T., Gandin, C., Lazdunski, M., Heurteaux, C.   +4 more
openaire   +2 more sources

A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTI-CENTRE, PHASE III STUDY OF MLC901 (NEUROAID IITM) FOR THE TREATMENT OF COGNITIVE IMPAIRMENT AFTER MILD TRAUMATIC BRAIN INJURY

medRxiv
Introduction: About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI.
I. Prof.Pavel, MD Pilipenko, Dr Anna A. Ivanova, Dr Yulia V. Kotsiubinskaya, N. Prof.Vera, M. Grigoryeva, AProf. Alexey, MD Y. Khrulev, Dr Anatoly V. Skorokhodov, Dr Maxim M. Gavrik, Dr. Nona N. Mkrtchan, Prof. Marek Majdan, P. Valkovic, Dr Daria Babarova, Prof. Suzanne Barker-Collo, A. Jones, L. Prof.Valery, MD PhD Feigin   +17 more
semanticscholar   +1 more source

The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES) for the NEURITE investigators

Cerebrovascular Diseases, 2013
Background: A substantial proportion of patients after nondisabling stroke are cognitively impaired compared to age- and education-matched community-dwelling controls. Moreover, poststroke patients who have 'vascular cognitive impairment no dementia' (VCIND) of moderate severity have a high risk of incident dementia, dependency and death.
Chen, C.L.H., Ikram, K., Anqi, Q., Yin, W.T., Chen, A., Venketasubramanian, N.   +5 more
openaire   +1 more source

A Potential Role Exists for Nutritional Interventions in the Chronic Phase of Mild Traumatic Brain Injury, Concussion and Sports-Related Concussion: A Systematic Review. [PDF]

Nutrients, 2023
Ryan T, Nagle S, Daly E, Pearce AJ, Ryan L.   +4 more
europepmc   +1 more source

Spinal cord injury - assessing tolerability and use of combined rehabilitation and NeuroAiD (SATURN) study - primary results of an exploratory study. [PDF]

J Spinal Cord Med, 2023
Kumar R, Htwe O, Baharudin A, Rhani SA, Ibrahim K, Nanra JS, Gsangaya M, Harun H, Kandar K, Balan M, Peh S, Pokharkar Y, Ingole A, Hisam Ariffin M.   +13 more
europepmc   +1 more source